首页> 外文期刊>Allergy and asthma proceedings >T-lymphocyte activation and the levels of eosinophilic cationic protein and interleukin-5 in asthmatic children with acute exacerbation and effect of glucocorticoid treatment.
【24h】

T-lymphocyte activation and the levels of eosinophilic cationic protein and interleukin-5 in asthmatic children with acute exacerbation and effect of glucocorticoid treatment.

机译:哮喘急性加重患儿的T淋巴细胞活化及嗜酸性阳离子蛋白和白细胞介素5的水平,以及糖皮质激素的治疗​​作用。

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this study was to evaluate the immunologic parameters and the effects of glucocorticoid treatment, the absolute numbers of CD4+/CD25+ T lymphocytes, eosinophil counts, levels of eosinophilic cationic protein (ECP), and interleukin (IL)-5 in peripheral blood of patients having acute asthma exacerbations and healthy children were investigated. Samples for the absolute numbers CD4+/CD25+ T lymphocyte and eosinophil count, ECP, and IL-5 were obtained before (day 1) and after (day 5) glucocorticoid treatment. Forced expiratory volume in 1 second and peak expiratory flow rate were measured on days 1 and 5 in asthma patients (n = 25) and in the control group (n = 15). The absolute numbers of CD4+/CD25+ T lymphocyte and eosinophils, levels of ECP, and IL-5 were significantly greater, while forced expiratory volume in 1 second and peak expiratory flow rate were significantly less in the patients with asthma than in the control subjects on day 1. These parameters normalized after glucocorticoid treatment with clinical improvement by day 5. Glucocorticoid treatment is associated with clinical and laboratory improvement achieved in patients with acute asthma exacerbations.
机译:这项研究的目的是评估免疫参数和糖皮质激素治疗的效果,外周血中CD4 + / CD25 + T淋巴细胞的绝对数量,嗜酸性粒细胞计数,嗜酸性阳离子蛋白(ECP)和白介素(IL)-5的水平对患有急性哮喘急性发作的患者和健康儿童进行了调查。在糖皮质激素治疗之前(第1天)和之后(第5天)获得了CD4 + / CD25 + T淋巴细胞和嗜酸性粒细胞计数,ECP和IL-5绝对数的样品。在哮喘患者(n = 25)和对照组(n = 15)的第1天和第5天测量了1秒的强制呼气量和最大呼气流速。哮喘患者的CD4 + / CD25 + T淋巴细胞和嗜酸性粒细胞的绝对数,ECP和IL-5的绝对值显着增加,而哮喘患者在1秒内的强制呼气量和最大呼气流速明显低于对照组。第1天。糖皮质激素治疗后这些参数正常化,第5天临床改善。糖皮质激素治疗与急性哮喘加重患者的临床和实验室改善相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号